Scynexis Inc. SCYX
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Scynexis Inc. (SCYX) is a healthcare company listed in the US with a market value of about $32M. In the twelve months to September 30, 2026 it had revenue of $19M and net income of -$10M, a net margin of -53.5%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 1.2, a 5-year average ROIC of -259%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.
About Scynexis
Scynexis is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $12M in 2014 to $21M in 2025, growth of about 5.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders). It spends 108% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $21M | $4M | $140M | $5M | $13M | $0 | $121000 | $257000 | $257000 | $257000 |
| Net income | -$10M | -$9M | -$21M | $67M | -$63M | -$33M | -$55M | -$54M | -$12M | -$25M | -$30M |
| Free cash flow | — | — | — | — | — | -$55M | -$49M | -$38M | -$29M | -$25M | -$29M |
| EPS (diluted) | $2.69 | $-0.17 | $-0.44 | $1.39 | $-1.47 | $-1.25 | $-5.15 | $-9.58 | $-2.84 | $-9.37 | $-15.80 |
| Net margin | -53.5% | -41.8% | -568.3% | 47.8% | -1233.7% | -249.7% | — | -44388.4% | -4851.4% | -9751.0% | -11668.9% |
| ROIC | — | -31.2% | -50.8% | 95.6% | -1239.7% | -70.5% | -185.5% | -300.9% | -39.2% | -73.0% | -56.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Scynexis’s P/E ratio?
About 1.2, based on the last twelve months of diluted earnings per share.
Is Scynexis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Scynexis pay a dividend?
Not currently.
Is Scynexis a good stock to buy?
We do not give buy or sell advice. Scynexis scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.